

RECEIVED

JUL 29 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Nabil Hanna

Group Art Unit: 1642

Application Serial No. 09/822,672

Examiner: L. Helms

Filed: April 2, 2001

Title: COMBINED USE OF ANTI-CYTOKINE ANTIBODIES OR ANTAGONISTS AND ANTI-CD20 FOR THE TREATMENT OF B CELL LYMPHOMA

* * * * *

RESPONSE TO RESTRICTION/ELECTION REQUIREMENT

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In Response to the Restriction/Election Requirement dated June 25, 2002, Applicants elect with traverse Group X, Claims 74-75 directed to treating B cell lymphoma with the combination of an anti-IL-10 antibody and a B cell depleting antibody.

Also, kindly introduce the following additional claims which correspond to the elected group.

In the Claims

Please amend Claim 75 as follows:

75. (Amended) the method of claim 74 wherein said B cell depleting antibody binds to a B cell antigen from the group consisting of CD19, CD20, CD22, CD23, CD27, CD37, CD53, CD72, CD73, CD74, CDw78, CD79a, CD79b, CD80, CD81, CD82, CD83, CDw84, CD85 and CD86.

Kindly add the following new claims 87-96.

--87. (New) The method of Claim 75 wherein the B cell depleting antibody binds CD20.

88. (New) The method of Claim 75 wherein the B cell depleting antibody binds CD23.

89. (New) The method of Claim 87 wherein said antibody is a chimeric anti-CD20 antibody.